Parameter | Overall cohort | Group 1 (3–4 × 106 CD34+ cells /kg bw) | Group 2 (2–2.5 × 106 CD34+ cells /kg bw) | P value Group 1 vs. 2 | Group 3 (< 2 × 106 CD34+ cells /kg bw) |
---|---|---|---|---|---|
ASCTs analyzed, n | 148 | 86 | 53 | / | 9 |
Sequential ABSCTs, n (%) | Â | Â | Â | / | Â |
 First | 142 (96) | 86 (100) | 53 (100) | 3 (33) | |
 Second | 5 (3) | 0 (0) | 0 (0) | 5 (56) | |
 Third | 1 (1) | 0 (0) | 0 (0) | 1 (11) | |
Remission pre ABSCT, n (%) | Â | Â | Â | 0.168a | Â |
 CR | 2 (1) | 2 (2) | 0 (0) | 0 (0) | |
 nCR | 38 (26) | 28 (33) | 9 (17) | 1 (11) | |
 VGPR | 48 (32) | 26 (30) | 21 (40) | 1 (11) | |
 PR | 45 (30) | 21 (24) | 18 (34) | 6 (67) | |
 MR | 4 (3) | 3 (3) | 1 (2) | 0 (0) | |
 SD | 1 (1) | 0 (0) | 1 (2) | 0 (0) | |
 PD | 6 (4) | 2 (2) | 3 (6) | 1 (11) | |
 NA | 4 (3) | 4 (5) | 0 (0) | 0 (0) | |
Median age at ASCT, years (range) | 61 (41–75) | 61 (44–73) | 62 (41–72) | 0.886 | 60 (50–75) |
Transplanted PBSCs | |||||
 Median transplanted CD34+ cells ×106/kg (range) | 3.2 (1.7–4.0) | 3.6 (3.0–4.0) | 2.3 (2.0–2.5) | < 0.001 | 1.9 (1.7–1.99) |
 Median vitality, % (range) | 79 (53–93) | 76 (53–93) | 81 (58–93) | 0.012 | 80 (66–93) |
HD chemotherapy, n (%) | Â | Â | Â | / | Â |
 Melphalan 2 × 100 mg/m2 | 146 (99) | 85 (99) | 53 (100) | 8 (89) | |
 Dose reduction | 2 (1) | 1 (1) | 0 (0) | 1 (11) | |
Remission post ASCT, n (%) | Â | Â | Â | 0.316b | Â |
 CR | 15 (10) | 11 (13) | 4 (8) | 0 (0) | |
 nCR | 42 (28) | 30 (35) | 11 (21) | 1 (11) | |
 VGPR | 54 (36) | 27 (31) | 22 (42) | 5 (56) | |
 PR | 25 (17) | 11 (13) | 12 (23) | 2 (22) | |
 MR | 5 (3) | 3 (3) | 2 (4) | 0 (0) | |
 SD | 1 (1) | 1 (1) | 0 (0) | 0 (0) | |
 PD | 2 (1) | 2 (2) | 0 (0) | 0 (0) | |
 NA | 4 (3) | 1 (1) | 2 (4) | 1 (11) |